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Abstract
Mitochondrial dysfunction due to nuclear or mitochondrial DNA alterations contributes to multiple diseases such as
metabolic myopathies, neurodegenerative disorders, diabetes and cancer. Nevertheless, to date, only half of the estimated
1,500 mitochondrial proteins has been identified, and the function of most of these proteins remains to be determined.
Here, we characterize the function of M19, a novel mitochondrial nucleoid protein, in muscle and pancreatic b-cells. We
have identified a 13-long amino acid sequence located at the N-terminus of M19 that targets the protein to mitochondria.
Furthermore, using RNA interference and over-expression strategies, we demonstrate that M19 modulates mitochondrial
oxygen consumption and ATP production, and could therefore regulate the respiratory chain activity. In an effort to
determine whether M19 could play a role in the regulation of various cell activities, we show that this nucleoid protein,
probably through its modulation of mitochondrial ATP production, acts on late muscle differentiation in myogenic C2C12
cells, and plays a permissive role on insulin secretion under basal glucose conditions in INS-1 pancreatic b-cells. Our results
are therefore establishing a functional link between a mitochondrial nucleoid protein and the modulation of respiratory
chain activities leading to the regulation of major cellular processes such as myogenesis and insulin secretion.
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Introduction
Mitochondria are cellular organelles involved in various critical
cell functions including ATP production, apoptosis, calcium
homeostasis and production of oxygen species. Mitochondria
contain their own DNA that is found in association with proteins
in organized structures called mitochondrial nucleoids. These
structures, that are thought to associate with the mitochondrial
inner membrane, have been shown to be essential for the
protection, maintenance and propagation of mitochondrial DNA
(mtDNA). The 37 genes present in the mtDNA encode
mitochondrial proteins, the large and small rRNA, and 22
tRNA. In humans, while only 13 mitochondrial genes encode
mitochondrial proteins, all part of the respiratory chain, it is
estimated that more than 1,500 mitochondrial proteins are
encoded by nuclear DNA (nDNA) [1], while only half of them
has been identified [2]. These nuclear gene-encoded proteins are
translated in the cytosol and therefore need to be transported
across one or both mitochondrial membranes using specific
targeting sequences that direct them to the different mitochon-
drial subcompartments [3,4].
Numerous studies have shown that mitochondria are implicated
in the regulation of cell differentiation. Indeed, it has been shown
that mitochondrial protein synthesis is essential for erythroleuke-
mia differentiation [5], that mitochondrial translation is necessary
for neuroblastoma differentiation [6], and that changes in
mitochondrial activity are closely associated with differentiation
of osteoblasts [7]. In avian myoblasts, alteration in mitochondrial
activity occurs before terminal differentiation [8]. Moreover,
inhibition of mitochondrial protein synthesis by tetracycline in
murine myoblasts leads to the impairment of muscle differentia-
tion accompanied by the down-regulation of some muscle-specific
genes such as muscle creatine kinase and troponin I, but does not
affect myogenin and MyoD expression levels [9]. More recently, it
has been demonstrated that inhibition of mitochondrial translation
by chloramphenicol in avian myoblasts results in a reversible
inhibition of muscle differentiation associated with a marked
decrease of myogenin expression but not of the two other muscle-
specific transcription factors, MyoD and Myf5 [10].
Studies have also demonstrated the importance of mitochondria
in the control of insulin secretion by the pancreatic b-cell. Indeed,
use of drugs affecting the respiratory chain, mutations in and
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critical role of mitochondrial activities on glucose-stimulated
insulin secretion. In this cell type, mitochondrial ATP production
appears to be a key factor linking intracellular glucose metabolism
and exocytosis of insulin granules, showing the importance of
mitochondria in pancreatic b-cells [11]. Moreover, mitochondrial
defects, including increased production of reactive oxygen species,
elevated uncoupling protein 2 activity and mitochondrial DNA
mutations, may participate in the impairment of glucose-induced
insulin secretion of pancreatic b-cells observed in type 2 diabetes
[12].
In a recent study, a novel mitochondrial nucleoid protein, M19,
has been identified in HeLa cells [13]. In order to specify the
cellular role of this newly described protein, we have characterized
a 13-long amino acid sequence located at the N-terminus of the
protein that targets the protein to mitochondria. Furthermore,
using RNA interference and over-expression strategies, we have
shown that mitochondrial respiratory chain activities, such as
oxygen consumption and ATP production, are regulated by M19
expression levels. Finally, we have demonstrated that M19,
through its modulation of the respiratory chain activity, is a
positive regulator of late skeletal muscle differentiation and insulin
secretion by pancreatic b-cells. Altogether, these data show the key
role of a novel mitochondrial nucleoid protein in physiological
processes such as mitochondrial ATP production, muscle
differentiation and insulin secretion.
Results
Expression and cellular localization of M19 in muscle cells
Recently, a novel mitochondrial protein, called M19, preferen-
tially expressed in brain, kidney, heart and skeletal muscle, has
been identified [13]. It has been shown that human M19 is
associated with mitochondrial nucleoids in HeLa cells and that it is
likely present in the peripheral region of nucleoids where it could
be involved in mtDNA translation and/or assembly of respiratory
complexes [13].
In order to gain insight into the function of M19 in muscle cells,
we have generated a rabbit polyclonal antibody, called P70612,
from the immunization of a rabbit with the bacterially expressed
human M19. We used the murine C2C12 cell line to determine
the expression level of the protein during skeletal muscle
differentiation. The purified polyclonal antibody P70612 recog-
nized predominantly a single band at about 18 kDa, in accordance
with a predicted molecular weight of 16.3 kDa for the mouse
protein (Figure 1A). Mouse M19 is detected in proliferating
myoblasts and its expression increases progressively upon
induction of differentiation (Figure 1A), highlighting its potential
role during differentiation/regeneration processes and in differ-
entiated skeletal muscle. We next examined the cellular localiza-
tion of mouse M19 in C2C12 cells, using the specific P70612
antibody. As seen in figure 1B-E, M19 colocalizes with
cytochrome c in the mitochondria of C2C12 myoblasts and
myotubes. In myoblasts, the studied protein is detected in short
filaments and dots (Figure 1B), while in myotubes, the staining is
more diffuse even though some staining is detected in faint
filaments (Figure 1D). Longitudinal sections of mouse Tibialis
anterior muscles were processed with the P70612 antibody.
Examination of these sections showed regular transversely oriented
rows of staining, similar to what is observed for cytochrome c
staining (Figure 1F, G).
To confirm the mitochondrial localization of mouse M19 in
C2C12 cells, we performed cell fractionation experiments using
C2C12 myoblasts. Immunoblot analyses of isolated mitochondria
extracts and cytosolic fractions of C2C12 cells show that tubulin is
found in the cytosolic fraction while, as expected, the mitochon-
drial extract is greatly enriched in COX IV, a mitochondrial
enzyme (Figure 1H). In accordance with the mitochondrial
localization of mouse M19 observed by fluorescence microscopy,
the studied protein is detected in the mitochondrial extract.
Furthermore, we subjected purified mitochondria from C2C12
myoblasts to limited trypsinization. This treatment allowed the
degradation of cytosolic proteins interacting with the mitochon-
drial outer membrane or intrinsic proteins of the outer membrane.
As a marker protein of the outer mitochondrial membrane, we
used the import receptor, Tom40. When intact mitochondria were
treated with increasing concentration of trypsin, Tom40 was
subjected to degradation while M19 was protected, suggesting that
the studied protein is not loosely bound to the outer membrane or
an intrinsic protein of the outer membrane (Figure 1I). To further
determine the intra-mitochondrial localization of M19, we
disrupted purified mitochondria with freeze/thaw cycles and then
subjected the homogenate to Na2CO3 precipitation followed by
centrifugation. This technique allowed us to separate the
mitochondrial membrane fraction from the matrix/intermem-
brane space fraction. Immunoblot analyses showed that the
mitochondrial marker VDAC is found, as expected, in the
membrane fraction. Interestingly, M19 is mostly detected in the
membrane fraction even though some protein is also present in the
matrix/intermembrane space fraction (Figure 1J). These digestion
and fractionation experiments strongly indicate that mouse M19
resides within mitochondria of C2C12 cells, likely at the interface
between the matrix and the inner membrane, in accordance with
the mitochondrial localization of M19 previously described in
HeLa cells [13].
M19 contains a functional mitochondrial targeting signal
Despite its mitochondrial nucleoid association, Sumitani et al.
did not describe any mitochondrial localization signal within
human M19 [13]. Nevertheless, the mitochondrial localization of
M19, the prediction of a potential cleavage site for a mitochondrial
targeting sequence between amino acid 9 and 10 (WoLF PSORT
software; http://wolfpsort.org/; data not shown), and the fact that
the protein is encoded in the nucleus led us to search for the
presence of a potential mitochondrial localization signal within the
protein. For most of the proteins targeted to the mitochondrial
matrix or the inner membrane, this signal is an amphipathic a-
helix localized at the N-terminus of the protein. We therefore used
four different algorithms to predict the secondary structure of M19
from the primary sequence of the mouse protein. The programs
predicted the presence of 6 to 7 a-helices within the protein, with
one localized at the N-terminus from amino acids 2 to 15
(Figure 2A). In order to determine whether this predicted N-
terminal a-helix is an amphipathic helix, an helical wheel
presentation of the 13 N-terminal amino acids of mouse M19
was generated as shown in Figure 2B. Interestingly, all positively
charged residues lie on one face of the putative helix while the
opposite face contains only hydrophobic residues. Furthermore,
helical wheel projections of the other predicted a-helices of the
protein showed no amphipathic feature (data not shown). This N-
terminal helical conformation corresponds therefore to an
amphipathic helical structure characteristic of mitochondrial
targeting signals.
To test whether the putative N-terminal amphipathic a-helix of
M19 is a functional mitochondrial targeting signal, we generated a
N-terminal truncation, D1–12, which deletes amino acids 1 to 12
corresponding to a major part of the helix. Wild-type M19 and the
D1–12 mutant, coupled to a C-terminal histidine tag, were
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wild-type protein is targeted to the mitochondria, while the D1–12
truncation completely abolished the mitochondrial localization of
theprotein(Figure2D).A similarresultwas obtainedusing ashorter
truncation deleting amino acids 7 to 12 of the protein (data not
shown). A more conclusive demonstration of the ability of the N-
terminal amphipathic a-helix to direct mitochondrial localization
was observed by fusing the amino acids 1 to 13 to the N-terminus of
GFP. While GFP is localized in the cytoplasm and the nucleus of
C2C12 myoblasts (Figure 2E), the 13 N-terminal amino acids of
M19 clearly directed GFP to mitochondria (Figure 2G). Interest-
ingly, when this amphipathic a-helix was fused to the C-terminus of
GFP, a diffuse cytoplasmic/nuclear staining was observed
(Figure 2I). Together, these data demonstrated that the N-terminal
Figure 1. Expression and localization of M19 in muscle cells. (A) Coomassie-blue stained gel and Western blot analysis of M19 in extracts
from C2C12 cells grown in proliferation medium (d0) or placed in differentiation-promoting conditions for 2 to 9 days (d2 to d9). M19 is detected by
the rabbit polyclonal P70612 antibody. (B, C) C2C12 myoblasts were grown in proliferation medium or (D, E) were placed in differentiation medium
for 6 days, and then were double-labeled with the specific P70612 antibody (B, D; green) and an anti-cytochrome c antibody (C, E; red). There is a
co-localization between the 2 detected proteins in C2C12 myoblasts (B, C, merge) and myotubes (D, E, merge) as indicated by arrowheads. (F, G)
Double-label indirect immunofluorescence of mouse Tibialis anterior sections showing M19 (F; green) and cytochrome c (G; red). (H) After C2C12
cell fractionation, proteins from the cytosolic and the mitochondria fractions were separated by SDS-PAGE. Tubulin, COX IV and M19 are detected by
Western immunobloting. (I) Purified mitochondria are subjected to limited degradation using increasing concentration of trypsin, from 0 to 80 mg/ml.
The mitochondria are then lysed in Laemmli buffer. Tom40 and M19 are detected by Western immunobloting. (J) Purified mitochondria are disrupted
with freeze/thaw cycles, followed by Na2CO3 precipitation. After centrifugation, the membrane fraction (memb) and the matrix/intermembrane space
fraction (matrix) are analyzed by Western immunobloting using a VDAC antibody and the P70612 antibody.
doi:10.1371/journal.pone.0031815.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31815Figure 2. Identification of a mitochondrial targeting signal. (A) Prediction of the secondary structure of mouse M19 (Mus musculus
NM026063) using 4 different algorithms: phyre, PSIPRED, SAM and jufo. The predicted a-helices are indicated by black lines along the amino-acid
sequence. (B) Helical wheel presentation of the N-terminal a-helix of mouse M19, from amino acid 1 to 13. Hydrophobic residues are indicated in
black circles while the positively charged amino acids are mentioned with a ‘‘+’’. The first methionine (amino acid 1), at the top of the figure, is
considered as a positively charged residue. (C, D) C2C12 myoblasts were transfected with the pQETriSystem vector encoding histidine-tagged M19
(C) or a histidine-tagged M19 mutant lacking amino acids 1 to 12 (D). Indirect immunofluorescence was performed using an anti-histidine antibody.
(E–J) C2C12 myoblasts were transfected with the pEGFP-N1 vector encoding GFP alone (E, F), the pEGFP-N1 vector encoding the N-terminal M19 a-
helix fused to the N-terminal end of GFP (G, H), and the PEGFP-C3 vector encoding the N-terminal M19 a-helix coupled to the C-terminal end of GFP
(I, J). Fluorescence microscopy allows the direct detection of GFP constructs (E, G, I; green) and the indirect detection of cytochrome c using an anti-
cytochrome c antibody (F, H, J; red).
doi:10.1371/journal.pone.0031815.g002
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protein to mitochondria.
M19 is a positive regulator of mitochondrial oxygen
consumption and ATP production
M19 has been shown to be associated with mtDNA and, more
precisely, it is supposed to be part of the peripheral region of
mitochondrial nucleoids [13]. It has been recently suggested that
mitochondrial transcription occurs in their central core while
mitochondrial translation and assembly of respiratory complexes
occur in the peripheral region [14]. Therefore, nucleoids appear
as mitochondrial key structures essential for the proper activity of
the respiratory chain. So, in order to define the cellular function
of M19 in C2C12 muscle cells, we decided to determine the
oxygen consumption and the ATP production levels of C2C12
cells lacking M19. To this end, we transfected C2C12 myoblasts
with a shRNA vector specific for mouse M19 or an empty
shRNA vector as a control. After 2 days in proliferation medium,
M19 was reduced by about 25% in M19 shRNA cells (Figure 3A).
In these cells, basal oxygen consumption was significantly altered
by 12%, compared to control shRNA cells (Figure 3B). Addition
of the mitochondria-specific ionophore CCCP, which alters
mitochondrial potential, induced an oxygen consumption in-
crease in control cells. Nevertheless, in presence of CCCP,
oxygen consumption was significantly reduced in cells lacking
M19 compared to control cells (Figure 3B). Concomitantly to this
reduced oxygen consumption determined in M19 shRNA cells, a
19%-decrease of cellular ATP was observed in these cells
(Figure 3C). In parallel, we also analyzed the effect of an
overexpression of M19 on oxygen consumption and ATP
production. We transfected C2C12 myoblasts with the pQE-
TriSystem vector alone or the pQETriSystem vector encoding
mouse M19 coupled to a 8-histidine tag (Figure 3D). Compared
to control cells, C2C12 cells overexpressing M19 showed a
significant 18%-increase in basal oxygen consumption, while in
presence of CCCP this increase was of 22% (Figure 3E).
Furthermore, we observed a 14%-ATP production increase in
C2C12 myoblasts overexpressing M19 (Figure 3F). Altogether,
these results suggest that M19 regulates oxidative phosphoryla-
tion in C2C12 cells.
Figure 3. M19 expression levels regulate oxygen consumption and ATP production in C2C12 cells. (A–C) C2C12 myoblasts were
transfected with a control pHYPER vector (sh control) or the pHYPER vector encoding a M19-specific shRNA (sh M19). Transfected cells were grown in
proliferation medium for 2 days and were then lysed in Laemmli buffer. (A) Cell extracts were processed for immunoblot analysis with the P70612
antibody and an anti-tubulin antibody for loading control. (B) Oxygen consumption was evaluated for control cells (sh control) and for M19-specific
shRNA cells (sh M19), in untreated cells or in cells treated with the ionophore CCCP. (C) ATP production was determined in control cells (sh control)
and in M19-specific shRNA cells (sh M19). (D–F) C2C12 myoblasts were transfected with the empty pQETriSystem vector (pQE control) or the
pQETriSystem vector encoding mouse M19 (pQE M19). (D) Cell extracts were resolved by SDS-PAGE. Endogenous M19 and exogenous histidine-
tagged M19 were detected by Western immunobloting using the P70612 antibody. (E) Oxygen consumption was evaluated for control cells (pQE
control) and for M19-overexpressing cells (pQE M19), in untreated or in CCCP-treated myoblasts. (F) ATP production was determined in control cells
(pQE control) and in M19-overexpressing cells (pQE M19). Results are the mean 6 SEM of two (E), three (B), or five (C, F) independent experiments. (*)
and (**) indicate statistical significance at p,0.05 and p,0.01, respectively, according to the unpaired Student’s t test.
doi:10.1371/journal.pone.0031815.g003
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human HeLa cell line. M19 is detected as a single band of about
17 kDa in HeLa cell extracts using the P70612 antibody, and is
localized within the mitochondria of HeLa cells as detected by indirect
immunofluorescence (data not shown). HeLa cells were transfected
with a siRNA specific for human M19 or with a control siRNA. The
cells expressing the specific siRNA displayed a loss of M19 expression
relative to control cells (Figure 4A; si control vs. si M19), accompanied
with a 26%-decrease of total ATP production (Figure 4B;si control vs.
si M19). Moreover, when GFP-coupled mouse M19 was overex-
pressed in HeLa cells, a 58%-raise of ATP production was observed
(Figure 4A, B; si control vs. si control/M19GFP), showing that mouse
M19 is functional in human HeLa cells. To assess the specificity of our
RNA interference strategy, human HeLa cells were double
transfected with the siRNA specific for human M19 and the pEGFP
vector encoding mouse M19, knowing that the specific siRNA for
human M19 is not able to alter mouse M19 expression (data not
shown). As can be seen, overexpression of mouse M19 in M19-
deficient HeLa cells (Figure 4A; si M19/M19GFP) restores ATP
production in these cells (Figure 4B; si M19 vs. si M19/M19GFP).
These data thus demonstrate the specificity of our RNA interference
strategy and confirm that M19 plays a fundamental role in cellular
ATP production.
Knowing that mitochondria are responsible for the production of
the majority of cellular ATP, we have investigated whether M19
modulates cytosolic ATP or mitochondrial ATP, using oligomycin,
a powerful inhibitor of mitochondrial ATP synthase. Treatment of
control HeLa cells with oligomycin induces a drop in cellular ATP
production corresponding to the loss of mitochondrial ATP, the
remaining ATP being cytosolic ATP (Figure 4C; si control vs. si
control/oligo). Interestingly, the use of a specific siRNA directed
against M19 does not further reduce ATP production in
oligomycin-treated cells (Figure 4C; si control/oligo vs. si M19/
oligo), indicating that M19 inhibition does not affect cytosolic ATP
production. Therefore, these experiments show that the mitochon-
drial nucleoid protein, M19, is a positive regulator of mitochondrial
ATP production.
M19 plays a role on late skeletal muscle differentiation
It has been previously shown that impairment of mitochondrial
function by various drug treatments leads to the inhibition of
muscle differentiation [9,10,15]. Because mitochondrial ATP
production is impaired in C2C12 myoblasts lacking M19, we
decided to determine whether M19 expression levels could
regulate muscle differentiation. Therefore, a possible inhibition
of muscle differentiation was studied in M19-deficient muscle cells.
C2C12 myoblasts transfected with a M19-specific siRNA were
placed in differentiation-promoting conditions for 7 days, and
M19 expression levels were detected by Western immunoblotting.
As can be seen in Figure 5A, during the entire differentiation
process, M19 expression is severely reduced in specific siRNA cells
compared to control cells. As a marker of late differentiation, the
expression levels of MHCII were determined in these M19-
deficient cells. Concomitantly to the reduction of M19, a loss of
MHCII expression was observed during the differentiation process
(Figure 5B), suggesting that late myogenesis is affected in cells
lacking M19. In accordance with this result, a loss of expression of
the late differentiation marker troponin T was also observed in
M19-deficient C2C12 cells placed in differentiation conditions for
5 to 7 days (data not shown). However, neither the expression of
early muscle differentiation effectors, such as MyoD and
myogenin, nor the formation of myotubes was affected in cells
lacking M19 (data not shown). Moreover, in C2C12 myotubes
transiently expressing a M19-specific shRNA associated with GFP,
MHCII was only expressed in small patches along the multinu-
cleated cells (Figure 5D, merge; arrowheads), while in control
myotubes, i.e. myotubes not expressing the specific shRNA,
MHCII was expressed abundantly along the entire cells
(Figure 5D, merge; asterisks). Interestingly, as shown in
Figure 5E, expression of other late markers of skeletal muscle
differentiation such as a-actinin 2, troponin T and MHCI was also
affected in M19-deficient cells grown in differentiation medium for
7 days. Altogether, these results show that M19, probably through
its regulation of respiratory chain activities, plays a role on late
myogenesis.
Figure 4. M19 expression levels regulate mitochondrial ATP production in HeLa cells. (A, B) HeLa cells were transfected with a control
siRNA (si control), a human M19-specific siRNA (si M19), a control siRNA associated with the pEGFP-N1 vector encoding mouse M19 (si control/
M19GFP), or a human M19-specific siRNA associated with the pEGFP-N1 vector encoding mouse M19 (si M19/M19GFP). (A) Expression levels of the
endogenous human M19 and the mouse GFP-coupled M19 are detected by Western immunobloting using the P70612 antibody. (B) ATP production
is presented for these transfected-HeLa cells. Results are the mean 6 SEM of five independent experiments. (***) indicates statistical significance at
p,0.001, according to the unpaired Student’s t test. (C) HeLa cells were transfected with a control siRNA (si control) or a human M19-specific siRNA
(si M19). ATP production was then determined in untreated or in oligomycin-treated cells (oligo). Results are the mean 6 SEM of four independent
experiments. (**) indicates statistical significance at p,0.01, and (n.s.) means statistically non significant, according to the Tukey HSD test used after
performing a one-way analysis of variance.
doi:10.1371/journal.pone.0031815.g004
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pancreatic b-cells
A Northern blot performed on human tissue extracts using a
specific probe for human M19 mRNA reveals that M19 mRNA is
indeed preferentially expressed in striated muscle as previously
described [13], but is also especially abundant in pancreas
(Figure 6A). It is well established that the mitochondrial ATP/
ADP ratio is one of the crucial regulators of insulin secretion in
pancreatic b-cells [16]. As we have shown that M19 is a positive
regulator of mitochondrial ATP production and therefore can
influence the cellular ATP/ADP ratio, we decided to study the
involvement of M19 on glucose-induced insulin secretion in
pancreatic b-cells. To test this, we used the rat insulinoma cell line
INS-1. As shown in Figure 6B, M19 colocalized with the
MitoTracker dye into the mitochondria of INS-1 cells. Further-
more, cell fractionation indicated that M19, like the mitochondrial
marker VDAC, was mostly present in the mitochondrial extract
isolated from INS-1 cells (Figure 6C). To examine whether
inhibiting M19 expression has an effect on insulin secretion, we
transfected INS-1 cells with a control shRNA vector or with the
mouse/rat M19-specific shRNA vector previously used with the
mouse C2C12 cell line. After 2 days of culture, M19 expression
was reduced by 38% in M19-specific shRNA cells compared to
control cells (Figure 6D). Concomitantly, a 25%-decrease in ATP
production was observed in M19-deficient INS-1 cells (Figure 6E).
Glucose-stimulated insulin secretion was then examined in these
cells using increasing amounts of glucose from 2.8 mM (basal) to
8.3 mM (high). Interestingly, a significant 27%-decrease in insulin
secretion was observed in M19-deficient INS-1 cells incubated
under basal glucose conditions (Figure 6F). However, high-glucose
stimulation, or addition of the mitochondrial substrate methyl-
succinate, a potent activator of insulin secretion, abolished the
Figure 5. Expression of late muscle differentiation markers is affected in differentiated M19-deficient C2C12 cells. (A, B) C2C12
myoblasts were transfected with a control siRNA (si control) or a M19-specific siRNA (si M19) and were then placed in differentiation medium for 7
days. Protein extracts from transfected cells grown in proliferation medium (d0) or in differentiation-promoting conditions for 3, 5 and 7 days (d3, d5,
d7) were analyzed by Western immunobloting using the M19-specific P70612 antibody (A) and a MHCII antibody (B). Densitometry analysis of the
detected bands is presented as the relative expression of M19 (A) and MHCII (B) normalized to tubulin. Results are the mean 6 SEM of three
independent experiments. (*) and (**) indicate statistical significance at p,0.05 and at p,0.01. In a similar experiment, C2C12 myoblasts were
transfected with the M19-specific shRNA vector allowing the expression of the specific shRNA with GFP. Cells were placed in differentiation medium
for 7 days. Fluorescence microscopy allows the direct visualization of GFP-labeled cells expressing the M19-specific shRNA (C, merge; green) and
the detection of MHCII using an anti-MHCII antibody (D, merge; red). (E) Protein extracts from control shRNA-transfected C2C12 cells (sh control)
and M19-specific shRNA-transfected C2C12 cells (sh M19) grown in differentiation-promoting conditions for 7 days were analyzed by Western
immunoblotting. The expression of the late muscle differentiation markers a-actinin 2, troponin T, MHCI and MHCII is shown, as well as the control
protein tubulin.
doi:10.1371/journal.pone.0031815.g005
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grown under basal glucose conditions (data not shown). Therefore,
these experiments suggest that in pancreatic b-cells, M19, through
its modulation of ATP production, plays a permissive role on
insulin secretion under basal glucose stimulation.
Discussion
Recently, Sumitani et al. published the first characterization of
the C6orf125 gene-encoded protein, M19, in HeLa cells [13]. They
showed that M19 is a novel mitochondrial matrix protein
associated with the inner membrane of the organelle [13]. Using
immunofluorescence microscopy, as well as biochemical assays, we
have confirmed the mitochondrial localization of M19 in muscle
cells, mostly in the inner membrane. Nevertheless, the lack of
hydrophobic transmembrane domain in M19 and the fact that we
have also detected the protein in the matrix suggest that M19
might be a matrix protein tightly associated with or anchored to
the inner membrane of the organelle. Interestingly, in search for a
potential mitochondrial localization signal within this nuclear-
Figure 6. Reduced insulin secretion in M19-deficient INS-1 cells. (A) Northern blot analysis of the M19 gene in human tissues. Pa: pancreas;
Ki: kidney; Sk: skeletal muscle; Li: liver; Lu: lung; Pl: placenta; Br: brain; He: heart. Molecular markers are shown on the left. (B) Fluorescence microscopy
of INS-1 cells double-labeled with the M19-specific P70612 antibody (M19, merge; green) and the MitoTracker dye (MitoTracker, merge; red). (C) Cell
fractionation of INS-1 cells. Proteins of the total cell lysate (Lys), the cytosolic (Cyt) and the mitochondria (Mi) fractions were subjected to Western
immunobloting. The cytosolic protein tubulin, the mitochondrial protein VDAC and M19 are detected. (D) INS-1 cells were transfected with a control
pHYPER vector (sh control) or with the pHYPER vector encoding a M19-specific shRNA (sh M19). Western immunoblot analysis of the cell extracts
shows expression levels of M19 and the control protein, tubulin. ATP production was determined in these cells (E), and insulin secretion was
measured under basal glucose conditions (F). Results are the mean 6 SEM of five (E), or four (F) independent experiments. (*) indicates statistical
significance at p,0.05.
doi:10.1371/journal.pone.0031815.g006
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acid long sequence, corresponding to an amphipathic a-helix,
which appears necessary and sufficient to target M19 to
mitochondria. Furthermore, using RNA interference and over-
expression strategies, we have demonstrated that M19 is a positive
regulator of mitochondrial oxygen consumption and ATP
production. Our results thus suggest that an impaired M19
expression affects the activity of the mitochondrial ATP synthase,
highlighting a direct or indirect role for M19 in mitochondrial
oxidative phosphorylation.
It has been recently shown that M19 is a component of
nucleoids in HeLa cells and, according to its fractionated pattern
in nucleoids, it has been suggested that M19 is more precisely
associated with the peripheral region of nucleoids [13]. A model
for a layered structure of mitochondrial nucleoids has been
proposed [14] in which the central core region contains the
mtDNA in tight association with proteins involved in replication
and transcription, surrounded by a peripheral region containing
proteins participating in the translation of mtDNA-encoded
proteins and their assembly into respiratory chain complexes.
Indeed, mitochondrial ribosomal proteins, chaperone proteins
such as LRPPRC which is thought to participate in the assembly
of complex IV, and subunits of complex I themselves are found in
the peripheral region of nucleoids [14,17]. Therefore, the fact that
M19 is located in this peripheral zone where it would regulate the
translation and/or the assembly of respiratory complex proteins is
in total accordance with the function of M19 we have described in
this manuscript, i.e. the modulation of respiratory chain activities
such as oxygen consumption and ATP production.
It is now well established that muscle differentiation is under the
control of mitochondrial activity. Indeed, inhibition of mitochon-
drial protein synthesis by different drugs leads to the inhibition of
myoblast differentiation [9,10]. Here, we have shown that a
decreased M19 expression affects late skeletal myogenesis of C2C12
myoblasts, as seen by the reduced expression of various skeletal
muscle proteins such as troponin T, a-actinin 2, MHCI and
MHCII. This suggests that the decreased ATP production observed
in M19-deficient cells could be responsible for the impaired cell
differentiation. Nevertheless, it has been shown that myoblast
differentiation impairment, induced by inhibition of mitochondrial
protein synthesis, was likely not due to modifications of intracellular
ATP levels [9,10]. Interestingly, it has also been shown that
respiratory chain impairment in myoblasts can modulate the
expression of several nuclear-encoded proteins such as muscle
creatine kinase, troponin I, myosin, calcineurin, and the transcrip-
tion factors myogenin, JNK-dependent ATF2, NF-kB and c-Myc
[9,10,18,19,20]. This recently described signaling pathway, linking
mitochondria to the expression of nuclear genes, has been named
mitochondria-to-nucleus retrograde signaling, or mitochondrial
stress signaling. Biswas and colleagues [18] have further demon-
strated that retrograde signaling was mediated by cytosolic Ca
++
concentration in C2C12 cells. More precisely, mitochondrial
membrane potential, mitochondrial ATP production and mito-
chondrial Ca
++ uptake can be affected by genetic or metabolic
stresses leading to an elevation of the cytosolic Ca
++ level and thus
resulting in the modulation of various protein expression. The data
reported in this paper indicate that impairment of M19 expression
affects mitochondrial ATP production. This mitochondrial stress
leads to the inhibition of the expression of various skeletal muscle
proteins essential for terminal differentiation of C2C12 myotubes.
Therefore, in M19-deficient cells, it is conceivable that mitochon-
drial metabolic stresses could induce retrograde signaling resulting
in a modified profile of nuclear gene expression and thus in an
impaired differentiation.
It is well documented that in pancreatic b-cells, the ATP/ADP
ratio is a crucial factor for the coupling of glucose metabolism to
insulin secretion [16], and that the determinants of mitochondrial
ATP production, such as cytosolic alkalization, glycolysis,
mitochondrial oxydative metabolism with also reactive oxygen
species production or mitochondrial uncoupling, play a crucial
role in this physiological process [11]. Therefore, impairment of
mitochondrial oxidative phosphorylation induced by a reduction
of M19 expression was likely to induce a defect of insulin secretion
in pancreatic INS-1 cells. Nevertheless, the effects we have seen on
insulin secretion were only observed under basal glucose
conditions. This suggests that M19 is a fine regulator of
mitochondrial ATP production and that a rise in mitochondrial
substrates, such as glucose or methyl-succinate, is able to bypass
the effect of a moderate decrease of M19 expression on insulin
secretion.
Type 1 diabetes results from an autoimmune destruction of
pancreatic b-cells and various association studies have revealed
that multiple genes contribute to disease susceptibility [21]. The
major genetic influences for type 1 diabetes have been mapped on
human chromosome 6 in a locus containing MHC class II genes
[22] and the ITPR3 gene [23], but other genes in or near this locus
have been suspected to contribute to type 1 diabetes risk.
Interestingly, the C6orf125/M19 gene is the gene directly
centromeric to the ITPR3 gene on human chromosome 6, these
two genes being separated by only 1,000 bp. Knowing that type 1
diabetes is a complex multigenic disorder, it would therefore be of
interest to study a possible association of the C6orf125/M19 gene
with this pathology.
In conclusion, our results show that the mitochondrial nucleoid
protein, M19, is involved in the regulation of mitochondrial ATP
production and therefore is able to modulate various cell activities
such as skeletal muscle differentiation/regeneration, or insulin
secretion by pancreatic b-cells. This is therefore the first
demonstration of the involvement of a nucleoid protein in such
physiological processes. Our efforts are now focused on the precise
mechanisms through which M19 regulates mitochondrial respira-
tory chain activity.
Materials and Methods
Cells
C2C12 and HeLa cells (ATCC# CRL-1772 and CCL-2,
respectively) were routinely cultured in proliferation medium:
Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, Switzer-
land), supplemented with 10% fetal bovine serum (FBS) (Gibco,
Invitrogen, Carlsbad, CA), 4.5 g/l glucose, 100 U/ml penicillin,
100 mg/ml streptomycin, 1 mM sodium pyruvate and 2 mM L-
glutamine (BioWhittaker, Walkersville, MD). C2C12 cell differ-
entiation was induced by switching FBS to 2% horse serum
(Biochrom-Seromed, France) in the medium. The insulin-secreting
cell line INS-1 was cultured as previously described [24]. Cells
were incubated in an atmosphere containing 5% CO2 at 37uC.
Antibodies and reagents
The polyclonal P70612 antibody was generated at the CRBM
animal facility, from the immunization of a rabbit with the full-
length bacterially expressed human M19. Mouse monoclonal anti-
a-tubulin, anti-myosin heavy chain II, anti-myosin heavy chain I,
anti-troponin T and anti-a-actinin 2 were purchased from Sigma-
Aldrich (St Louis, MO), mouse monoclonal anti-cytochrome c
from BD PharMingen (Franklin Lakes, NJ), mouse monoclonal
anti-Penta-His from Qiagen (Hilden, Germany), rabbit polyclonal
anti-COXIV from Cell Signaling technology (Danvers, MA),
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MyoD (C-20) and rabbit polyclonal anti-myogenin (M225) from
Santa Cruz Biotechnology, Inc (Santa Cruz, CA). The Mito-
Tracker Deep Red 633 dye is from Molecular Probes (Eugene,
OR).
Immunostaining
10 mm-cryosat sections of mouse Tibialis anterior muscles were
saturated with a PBS-BSA (Bovine Serum Albumin) 1% solution
during 15 min at 37uC. They were then labeled with primary
antibodies diluted in PBS-BSA 1% during 30 min at 37uC. After
washing, sections were probed with Texas Red-conjugated anti-
mouse IgG (Molecular Probes) and FITC-conjugated anti-rabbit
IgG (Molecular Probes).
C2C12 and HeLa cells, grown on glass coverslips, were fixed in
3.7% formaldehyde in PBS followed by a 5 min permeabilization
in 0.1% Triton X-100 in PBS. INS-1 cells were seeded on poly-L-
lysine (Sigma-Aldrich) coated Lab-Tek Chamber Slide System
(Nunc, Rochester, NY). Live INS-1 cells were stained for
45 minutes with the mitochondrion-selective dye MitoTracker
DeepRed 633, according to the manufacturer’s protocol. After
fixation with 2% paraformaldehyde for 20 min, the cells were
permeabilized 5 min in 0.1% Triton X-100 and saturated in 2%
BSA. Revelation was performed using various antibodies men-
tioned above. Images were captured with a MicroMax 1300 CCD
camera (charge-coupled-device camera; RS-Princeton Instru-
ments, Trenton, NJ) driven by MetaMorph software (v.4.11;
Universal Imaging Corp., Westchester, PA) on a Zeiss Axioimager
microscope (Carl Zeiss, Oberkochen, Germany).
SDS-PAGE and Western immunobloting
Samples were boiled 5 min at 95uC, separated on 15% SDS-
polyacrylamide gels and transferred onto nitrocellulose or PVDF
membranes. Proteins of interest were revealed by specific
antibodies mentioned above, followed by enhanced chemilumi-
nescence. Scanned radiographs were quantified with ImageJ
(National Institutes of Health, Bethesda, MD).
Subcellular fractionation and trypsin digestion
To isolate mitochondria from INS-1 cells and C2C12
myoblasts, cells were pelleted by centrifugation for 5 min at
900 g and then washed with PBS. Cell pellets were resuspended in
ice-cold mitochondrial isolation buffer (210 mM mannitol, 70 mM
sucrose, 1 mM EDTA, 10 mM Hepes pH7.5 with inhibitor
protease cocktail) and were homogenized with a Dounce. Nuclei
and unbroken cells were removed by centrifugation for 10 min at
800 g at 4uC. Mitochondria were pelleted by further centrifuga-
tion for 15 min at 15,000 g at 4uC. Equal protein amount of
cytosolic and mitochondrial fractions were separated by SDS-
PAGE.
In order to examine trypsin accessibility, 100 mg of mitochon-
dria prepared as described above were resuspended in mitochon-
drial isolation buffer and treated with increasing amount of trypsin
(0, 40, 80 mg/ml) for 20 min on ice. The reaction was stopped by
addition of protease inhibitors. Mitochondria were then pelleted
by a 20 min-centrifugation at 15,000 g, resuspended in 2X
Laemmli buffer and proteins were then separated by SDS-PAGE.
Plasmid constructions
The full-length open reading frame (orf), as well as a deletion
mutant lacking nucleotides 1 to 36 (D1–12 mutant), of mouse M19
were cloned into the pQE-TriSystem vector (Qiagen, Hilden,
Germany), which allows the expression of 8xHis-tagged proteins.
The first 39 nucleotides of the mouse M19 orf corresponding to
the 13 N-terminus amino acids of M19, or the full-length orf of
mouse M19, were PCR-amplified and cloned into the pEGFPN1
and pEGFPC3 vectors (Clontech Laboratories, Mountain View,
CA).
RNA interference strategy
siRNA, directed against human M19 cDNA, were synthesized
by GeneCust. To optimize the effect, we used a mix of 3 siRNA
targeting the following 3 DNA sequences: (59- CCA CAG ACA
CCU UGG AGG Att -39), (59- GGA AAU AGA UAA AGG CAU
Gtt -39), (59- GGA AGA AAC UGC AGG AGA Att -39). As a
control, a siRNA corresponding to a sequence that targets no
known messenger was used: 59- UUC UCC GAA CGU GUC
ACG U -39. HeLa cells, grown in 24-well plates, were transfected
with 4 mg of the siRNA mix or the control siRNA using
oligofectamine (Invitrogen, Carlsbad, CA).
Oligonucleotides, targeting the mouse M19 sequence 59- GCC
TGT CCG TGG AAG AGT A -39, were annealed and then
cloned into the pHYPER vector, a modified pEGFPN1 vector
allowing GFP expression combined to shRNA expression. The
control shRNA sequence used was identical to the control
sequence designed for the siRNA strategy. 4 mg of the plasmid
were then transfected into C2C12 grown into 60 mm-dishes using
JetPei (Polyplus-transfection, New York, NY), according to the
instructions provided by the manufacturer.
ATP assay
C2C12 cells, grown in 60 mm-dishes, were transfected with
4 mg of either the pQE vectors for over-expression experiments or
the pHYPER vectors for RNA interference experiments. HeLa
cells grown in 24-well plates were transfected with the siRNA mix
or the control siRNA alone. One day after, HeLa cells were
transfected a second time with the pEGFP/mouse M19 vector for
the rescue experiment. Following transfection, C2C12 cells were
grown 2 days in proliferation medium while HeLa cells were
grown for 1 day under the same conditions. Cells were then
trypsinized and 75,000 cells/well were placed in opaque 96-well
plates. INS-1 cells were seeded directly on opaque 96-well plates at
a density of 40,000 cells/well, and transfection with pHYPER
vectors was performed as described below. The CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison, WI) was
then used to determine intra-cellular ATP concentration,
according to the instructions provided by the manufacturer. In
some experiments, HeLa cells were treated for 1 hour with
62.5 mM oligomycin before determining ATP concentration.
Cellular respiration assay
C2C12 cells were washed with PBS, trypsinized and resus-
pended in DMEM. 2,5 million cells in 2 ml were transferred in
two sealed thermostated chambers (37uC) of high resolution
oxygraph (oxygraph-2k) (Oroboros Instruments, Innsbruck, Aus-
tria). Basal respiration was measured, and then non-phosphory-
lating/uncoupled respiration was determined in the presence of
the ATP synthase inhibitor, oligomycin, at a final concentration of
1.25 mM. Carbonylcyanide-3-chlorophenylhydrazone (CCCP), a
chemical uncoupler, was titrated into the cell solution to determine
maximal oxidative capacity. Then, complex I was inhibited by
rotenone (0.25 mM) and complex III was inhibited by antimycin
(4.4 mM). This final value of oxygen consumption was subtracted
from all the different measurements for the calculation of specific
oxygen consumptions. All the reagents were diluted in EtOH and
were purchased from Sigma.
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A human multi-tissue Northern blot (Clontech, Mountain View,
CA) containing 2 mg of poly(A)
+ mRNA from adult tissues was
used for hybridization analysis. A DNA fragment was amplified by
PCR from the full-length human M19 cDNA. The PCR product
was labeled with [a-
33P]dATP and used as a probe on the filter.
The filter was then exposed to a phosphor screen. Actin and
ubiquitin cDNAs were used as probes to check the presence of
similar levels of RNA in each lane.
Insulin secretion assay
INS-1 cells were seeded on poly-L-lysine coated 24-well plates
at a density of 350,000 cells/well. After 3 days of culture, cells were
transfected with the control or the mouse/rat M19-specific
pHYPER vector using Lipofectamine Plus Reagent (Invitrogen),
according to the manufacturer’s protocol. Forty eight hours after
transfection, cells were washed and pre-incubated for 1 h at 37uC
in KRB buffer (108 mM NaCl, 1.19 mM KH2PO4, 4.74 mM
KCl, 2.54 mM CaCl2, 1.19 mM MgSO4, 18 mM NaHCO3)
containing 2 g/l BSA in the absence of glucose. After removal of
the medium, the cells were incubated for another hour at 37uCi n
the same buffer in the presence of increasing amounts of glucose
(2.8, 5.6, 8.3 mM) with or without methyl-succinate (Sigma-
Aldrich). At the end of the incubation period, the medium was
collected and insulin was measured by HTRF insulin assay
(Cisbio, Bagnols/Ce `ze, France).
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